Therapies that focus on tumors’ use of fat and activate a variety of cell death that relies on fat molecules might be a promising solution to treat cancer, in line with a brand new study from UTHealth Houston.
The findings were published today in and were co-led by Daniel E. Frigo, PhD, professor on the University of Texas MD Anderson Cancer Center and college member on the University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences.
The researchers got here to this conclusion through a review of 121 external studies that examined the connection between lipid metabolism and the progression of varied sorts of carcinoma, a cancer that begins within the tissue lining of the skin.
“Lipids could make cancer more aggressive,” said co-principal investigator Mikhail Kolonin, PhD, director of the Center for Metabolic and Degenerative Diseases on the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases at McGovern Medical School at UTHealth Houston. “Nonetheless, there’s a lipid-dependent mechanism that may be activated to fight cancer.”
Lipids are the differing types of fat molecules which might be crucial to an individual’s health. Because cancer cells and fatty tissue, which temporarily stores lipids, communicate with one another, tumors can use lipids to grow or spread. But while body fat can promote cancer progression, it might also cause a variety of cell death often known as ferroptosis.
Ferroptosis occurs when lipid peroxides accumulate on cell membranes. Lipid peroxides are produced through the body’s normal activities, but when too a lot of them construct up, they’ll grow to be toxic.
Common cancer treatments reminiscent of chemotherapy and radiation kill cancer cells by forcing them to undergo a unique variety of cell death. Nonetheless, certain cancers can grow to be immune to common treatments.
Understanding the interaction between lipids and tumors could pave the best way for cancer therapies that focus on ferroptosis-inducing chemicals and suppress a tumor’s lipid utilization, Kolonin said.
“The implication is that there are specific therapeutic approaches that might potentially be developed to focus on specific mechanisms liable for lipid processing by the tumors,” said Kolonin, who can be the Harry E. Bovay, Jr. Distinguished University Chair in Metabolic Disease Research at McGovern Medical School.
Kolonin said the review also underscores the importance of labor on the Center for Metabolic and Degenerative Diseases geared toward determining the role of cellular aging on cancer progression and cachexia, or unintentional weight reduction, attributable to some sorts of tumors.
Additional authors at UTHealth Houston include Hong Anh Cao and Joseph Rupert, PhD. Kolonin is a college member at MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences.
The study was supported partially by the Bovay Foundation and the Levy-Longenbaugh Fund.
